IL11 and breast carcinoma: Among them, IL-1β, IL-6, IL-8, IL-11, and IL-17 have been extensively validated as mediators of bidirectional communication between bone cells and breast cancer cells, making them potential therapeutic targets (Haider et al., 2021; Zhou and Tulotta Cottewell, 2022; Shibabaw and Teferi Bayelign, 2023).